2012

  • CardiAQ Valve Technologies Raises $37.3M Series B

    November 29, 2012

    Nov. 29, 2012 : CardiAQ™ Valve Technologies, Inc., a privately held medical device company developing technologies for percutaneous mitral heart valve replacement, announced today that it received $37.3 million in funding in its second round of equity financing. OrbiMed led the round and was joined by Versant Ventures, Advent Life Sciences and existing investors. The funding, which incorporates conversion of a 2011 bridge financing, will be used to further validate the Company’s TMVI technology and is expected to carry the Company through its feasibility and CE mark clinical trials. Concur

    Read More
  • Vascular Graft Solutions Presents VEST trial at EACTS

    October 27, 2012

    October 27, 2012: Vascular Graft Solutions presents VEST trial at EACTS Live video box presentation: External mesh for vein grafting Press Release

    Read More
  • Laurantis Pharma Completes Funding Round

    September 4, 2012

    September 4, 2012: Laurantis Pharma completes funding round for research program First Human Trial of Lymfactin, Investigational Treatment for Breast Cancer-Associated Lymphedema, Receives Funding From Broadview Ventures Press Release

    Read More
  • CellAegis Devices, Inc. announces use of autoRIC™ during MI

    August 27, 2012

    August 27, 2012: CellAegis Devices announces first clinical program to use the Company’s autoRIC™ Device for remote ischemic conditioning [RIC] during myocardial infarction.   CellAegis-Press-Release-First-Clinical-Program

    Read More
  • CellAegis Devices, Inc. Receives CE Mark

    July 18, 2012

    July 18, 2012: CellAegis Devices, Inc., announced today that it has received a CE Mark for the Company’s autoRIC™ Device, which for the first time allows simple, consistent, reliable and cost-effective automation of remote ischemic conditioning (RIC) at the point of care.  CellAegis’ auto (RIC) Device has been developed for acute care applications in the ambulance, emergency room and other hospital settings, or for chronic treatment in the home. CellAegis-CE-Mark-Press-Release

    Read More
  • Capricor, Inc. Receives FDA Approval

    July 9, 2012

    July 9, 2012: CapriCor Inc. Announces FDA Approval To Initiate ALLSTAR Trial of Allogeneic Stem Cell Therapy In Patients Following Heart Attack. Capricor-Press-Release  

    Read More
  • CardiAQ Valve Technologies announces first implantation of TMVR

    June 14, 2012

    June 14, 2012: CardiAQ Valve Technologies (CardiAQ), which has developed the world’s first self-conforming and self-anchoring technology for nonsurgical Transcatheter Mitral Valve Implantation (TMVI), today announced that the Company has achieved a cardiovascular medicine milestone: a bioprosthetic mitral heart valve was successfully implanted as a compassionate treatment into an 86-year-old male suffering from severe mitral regurgitation (MR 4+). CVT-Press-Release

    Read More
  • miRagen Therapeutics publishes in Cell

    April 26, 2012

    April 26, 2012: MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today that scientific results published in the journal Cell reveal the central role of the heart in whole-body metabolism.  The data suggests that miRagen’s lead program, MIRG-9103 (antimiR-208), in addition to providing benefit in the setting of cardiac dysfunction, may have therapeutic utility in a variety of metabolic disorders that contribute to Metabolic Synd

    Read More
  • Apama Medical Raises $1M from Broadview Ventures

    January 20, 2012

    January 20, 2012 Apama Medical Press Release Over the past six months, we have been working diligently to raise funding for the ongoing development of Apama Medical.  As a result of those efforts, I am pleased to announce we have successfully closed a $1,000,000 financing with Broadview Ventures, Inc., of which we have received the first tranche of $750,000.  Established in 2008, Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.  As such, we are hon

    Read More